Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DNLI logo DNLI
Upturn stock ratingUpturn stock rating
DNLI logo

Denali Therapeutics Inc (DNLI)

Upturn stock ratingUpturn stock rating
$15.65
Last Close (24-hour delay)
Profit since last BUY1.03%
upturn advisory
Consider higher Upturn Star rating
BUY since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: DNLI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

19 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $31.5

1 Year Target Price $31.5

Analysts Price Target For last 52 week
$31.5 Target price
52w Low $10.57
Current$15.65
52w High $33.33

Analysis of Past Performance

Type Stock
Historic Profit -25.13%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.29B USD
Price to earnings Ratio -
1Y Target Price 31.5
Price to earnings Ratio -
1Y Target Price 31.5
Volume (30-day avg) 19
Beta 1.36
52 Weeks Range 10.57 - 33.33
Updated Date 08/28/2025
52 Weeks Range 10.57 - 33.33
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.81

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.71
Actual -0.72

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -24.99%
Return on Equity (TTM) -39.69%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1428517536
Price to Sales(TTM) 3643.65
Enterprise Value 1428517536
Price to Sales(TTM) 3643.65
Enterprise Value to Revenue 2843.16
Enterprise Value to EBITDA -8.66
Shares Outstanding 146212000
Shares Floating 131925876
Shares Outstanding 146212000
Shares Floating 131925876
Percent Insiders 9.83
Percent Institutions 96.3

ai summary icon Upturn AI SWOT

Denali Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Denali Therapeutics Inc. was founded in 2015 by scientists and entrepreneurs committed to defeating neurodegenerative diseases. The company focuses on discovering and developing therapies for diseases like Alzheimer's and Parkinson's.

business area logo Core Business Areas

  • Small Molecule Programs: Denali is developing small molecule therapeutics designed to cross the blood-brain barrier and target specific mechanisms involved in neurodegeneration.
  • Antibody Transport Vehicle (ATV) Technology: Denali's ATV technology facilitates the delivery of large molecule therapeutics, like antibodies and enzymes, across the blood-brain barrier to treat CNS diseases.
  • Engineered Enzymes: This involves designing and developing recombinant enzymes to address lysosomal dysfunction, a hallmark of many neurodegenerative diseases.

leadership logo Leadership and Structure

Denali is led by Ryan Watts, Ph.D., CEO, and a team of experienced pharmaceutical executives. The company has a functional organizational structure, with dedicated teams for research, development, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Takeda Collaboration Programs: Denali has a collaboration with Takeda Pharmaceutical for therapies targeting neuroinflammation in neurodegenerative diseases. While specific market share isn't publicly available, the collaboration represents a significant source of funding and potential revenue. Competitors include companies with neuroinflammation programs, such as Biogen (BIIB) and Roche (RHHBY).
  • SAR443820 (DNL310): DNL310 is a recombinant enzyme designed to treat Hunter syndrome. It is partnered with Sanofi (SNY). Market share data is not yet available as the product is in clinical trials. Competing approaches are enzyme replacement therapies like Elaprase from Takeda.
  • DNL788: DNL788 is a RIPK1 inhibitor being developed for systemic autoimmune diseases. Market share data is not available. Other companies developing RIPK1 inhibitors include GSK.

Market Dynamics

industry overview logo Industry Overview

The neurodegenerative disease market is large and growing, driven by an aging population and the lack of effective treatments. The market is highly competitive and fragmented.

Positioning

Denali Therapeutics is positioned as a leader in developing therapies that can cross the blood-brain barrier, a major challenge in treating CNS diseases. Their ATV technology gives them a competitive advantage.

Total Addressable Market (TAM)

The neurodegenerative disease market is projected to reach hundreds of billions of dollars. Denali is positioned to capture a significant portion of this TAM with its innovative drug delivery technology.

Upturn SWOT Analysis

Strengths

  • Novel blood-brain barrier technology (ATV)
  • Strong scientific expertise in neurodegeneration
  • Strategic partnerships with major pharmaceutical companies
  • Deep pipeline of drug candidates

Weaknesses

  • High cash burn rate
  • Clinical trial risk
  • Dependence on partnerships for funding
  • Limited commercialization experience

Opportunities

  • Expanding the application of ATV technology to new therapeutic areas
  • Advancing pipeline candidates through clinical development
  • Acquiring complementary technologies or companies
  • Securing additional partnerships for drug development and commercialization

Threats

  • Clinical trial failures
  • Competition from other companies developing CNS therapies
  • Regulatory hurdles
  • Changes in the reimbursement landscape

Competitors and Market Share

competitor logo Key Competitors

  • Biogen (BIIB)
  • Roche (RHHBY)
  • Eli Lilly (LLY)
  • AbbVie (ABBV)

Competitive Landscape

Denali's advantage lies in its ATV technology, but it faces competition from larger, more established pharmaceutical companies with greater resources.

Growth Trajectory and Initiatives

Historical Growth: Denali's historical growth has been driven by its pipeline advancement and strategic partnerships. The company has experienced significant growth in its research and development activities.

Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline candidates. Analyst estimates vary, but generally anticipate continued growth in revenue and R&D spending.

Recent Initiatives: Recent initiatives include advancing key pipeline candidates into later-stage clinical trials and expanding partnerships with pharmaceutical companies.

Summary

Denali Therapeutics is a promising biotech company focused on neurodegenerative diseases. Its ATV technology is a key differentiator, but clinical trial success and financial stability are crucial. Collaborations provide needed capital but can dilute future revenue streams. Overcoming clinical risks and securing funding remain pivotal for its continued success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Denali Therapeutics Inc. Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute investment advice. Market share figures are estimates and may not be precise. Financial data should be verified through official company reports.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Denali Therapeutics Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2017-12-08
Co-Founder, President, CEO & Director Dr. Ryan J. Watts Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 486
Full time employees 486

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.